PureTech Health Plc Ret. no patrimônio
Qual é o Ret. no patrimônio de PureTech Health Plc?
O Ret. no patrimônio de PureTech Health Plc é -21.58%
Qual é a definição de Ret. no patrimônio?
O retorno sobre o patrimônio é uma medida da lucratividade de um negócio em relação ao valor contábil do patrimônio líquido. É calculado pela divisão do lucro líquido do exercício pelo total do patrimônio líquido.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. no patrimônio de empresas na Setor Health Care em LSE em comparação com PureTech Health Plc
O que PureTech Health Plc faz?
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Empresas com ret. no patrimônio semelhantes a PureTech Health Plc
- Harvest Gold tem Ret. no patrimônio de -21.61%
- Aura Resources tem Ret. no patrimônio de -21.61%
- First Light Capital Corp tem Ret. no patrimônio de -21.59%
- Great Southern Mining tem Ret. no patrimônio de -21.59%
- Rambler Metals and Mining PLC tem Ret. no patrimônio de -21.58%
- Rambler Metals and Mining PLC tem Ret. no patrimônio de -21.58%
- PureTech Health Plc tem Ret. no patrimônio de -21.58%
- KEFI Minerals Plc tem Ret. no patrimônio de -21.58%
- International Business Settlement tem Ret. no patrimônio de -21.56%
- Leading Edge Materials tem Ret. no patrimônio de -21.53%
- Leading Edge Materials tem Ret. no patrimônio de -21.53%
- Quantum Graphite tem Ret. no patrimônio de -21.51%
- Magnis Technologies tem Ret. no patrimônio de -21.50%